AIS Biotech is developing glycomimetic-based anti-infectives that act as decoys to prevent pathogen adhesion, bypassing resistance mechanisms.

Antabio is a a privately-held clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.

ASTREMIHA Therapeutics is developing broad-spectrum antivirals aimed at blocking viral replication and strengthening the immune system to combat infections.

Aurobac Therapeutics is a biotechnology company founded in 2022 by Boehringer Ingelheim, Evotec, and bioMérieux to develop the next generation of antibiotics and products to combat antibiotic resistance.

Biocellis develops ultra-sensitive, bioluminescence-based diagnostics for next-generation immunoassays. Scalable, fast, and point-of-care ready.

BrightSens Diagnostics specializes in the development and commercialization of in vitro diagnostic (IVD) solutions, with a focus on improving the early detection of infectious diseases and accelerating clinical decision-making for the benefit of patients and healthcare professionals.

DAMOCLES is a French deep-tech start-up, founded in 2023, developing a rapid, decentralized, and actionable microbiological diagnostic solution that enables more precise targeting of the bacteria responsible for infections and significantly reduces the overuse of broad-spectrum antibiotics.

En Carta Diagnostics is a deep-tech company that develops rapid point-of-care (POC) molecular diagnostic kits. The company focuses primarily on the early diagnosis of Lyme disease.

Exeliom Biosciences is a clinical-stage biotech company developing next-generation innate immunomodulators designed to restore and strengthen the immune response in patients with cancer, inflammatory diseases, and chronic infections.

Founded in 2009, Fabentech is a company specializing in the development and production of treatments based on polyclonal antibodies. Fabentech combats biological agents identified as priorities by government authorities and major threats to public health.

Hermione Therapeutics is developing a platform for innovative treatments against various pathogens, based on a human hormone, with an initial project targeting Pseudomonas aeruginosa.

IAGE specializes in environmental biological analysis thanks to its expertise in molecular biology techniques, such as digital PCR.

Since 2019, Inteliphage has been developing a personalized phage therapy platform that it aims to industrialize at the European level starting in 2026 to combat multidrug-resistant infections.

The Jean-Jacques Laffont Foundation aims to provide funding for, develop, and promote cutting-edge research in economics and social sciences at the Toulouse School of Economics.

LovalTech is leading a project to develop a nasal protein vaccine based on research conducted by Biomap at the University of Tours and INRAE.

MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.

Microplate Dx is a diagnostics company focused on addressing a fundamental challenge in infectious disease management: enabling clinicians to select the right antibiotic, first time, at the point of care.

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines.

Osta Therapeutics develops smart novel antibiotic molecules to combat antibiotic resistance.

PHAGENIX is a specialty pharmaceutical company founded in 2025 with the obejctive of becoming a global leader in phage therapy and addressing the significant unmet medical need caused by severe drug-resistant infections.

PREVIA MEDICAL develops digital biomarkers capable of analyzing the data of thousands of patients in real time, identifying at-risk patients, and immediately alerting medical staff.

RNAlead provides its partners with a proprietary, powerful, versatile, and proven gene delivery technology. It supports its partners in the successful development of drug candidates (including vaccines and RNA gene therapy) from preclinical research through to clinical applications—with a fully integrated solution.

Spegegant leverages epidemiological and health economic modeling in two broad areas: market access, and epidemic prevention and control.

SYNERG–ID is a non–profit organisation that brings together public and private stakeholders to promote the use of data on infectious diseases.

Vaxinano is dedicated to developing innovative vaccines targeting veterinary and human infectious diseases including zoonotic diseases, in line with the One Health approach.

WEEZION is developing an innovative solution for diagnosing microbial infections in the blood that can identify pathogens and determine their antibiotic resistance in less than 90 minutes, enabling the implementation of targeted antibiotic therapy.